Evidence map›Paper›PMID 34278534›Full record

ArticleMikrochimica acta2021

Rapid, label-free, and sensitive point-of-care testing of anti-SARS-CoV-2 IgM/IgG using all-fiber Fresnel reflection microfluidic biosensor.

Wenjuan Xu, Jiayao Liu, Dan Song, Chunsheng Li, Anna Zhu, Feng Long

Open access · bronzeAbstract read
In one paragraph

Article in Mikrochimica acta, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Wenjuan Xu *School of Environment and Natural Resources, Renmin University of China, Beijing, 100872, China.
Jiayao Liu *School of Environment and Natural Resources, Renmin University of China, Beijing, 100872, China.
Dan Song *School of Environment and Natural Resources, Renmin University of China, Beijing, 100872, China.
Chunsheng LiBiology Institute of Hebei Academy of Sciences, Shijiazhuang, China.
Anna ZhuState Key Laboratory of NBC Protection for Civilian, Beijing, 102205, China. chuanna0306@163.com.
Feng LongSchool of Environment and Natural Resources, Renmin University of China, Beijing, 100872, China. longf04@ruc.edu.cn.ORCID http://orcid.org/0000-0002-3372-0624
Renmin University of China · CNHebei Academy of Sciences · CNNational Institute for Radiological Protection · CN

Funding

National Key Scientific Instrument and Equipment Development Projects of China 2012YQ3011105National Natural Science Foundation of China 21675171
6 · The paper itself

Abstract

The ongoing global pandemic of SARS-CoV-2 has promoted to develop novel serological testing technologies since they can be effectively complementary to RT-PCR. Here, a new all-fiber Fresnel reflection microfluidic biosensor (FRMB) was constructed through combining all-fiber optical system, microfluidic chip, and multimode fiber bio-probe. The transmission of the incident light and the collection and transmission of Fresnel reflection light are achieved using a single-multi-mode fiber optic coupler (SMFC) without any other optical separation elements. This compact design greatly simplifies the whole system structure and improves light transmission efficiency, which makes it suitable for the label-free, sensitive, and easy-to-use point-of-care testing (POCT) of targets in nanoliter samples. Based on Fresnel reflection mechanism and immunoassay principle, both the SARS-CoV-2 IgM and IgG antibodies against the SARS-CoV-2 spike protein could be sensitively quantified in 7 min using the secondary antibodies-modified multimode fiber bio-probe. The FRMB performs in one-step, is accurate, label-free, and sensitive in situ/on-site detection of SARS-CoV-2 IgM or IgG in serum with simple dilution only. The limits of detection of SARS-CoV-2 IgM and SARS-CoV-2 IgG were 0.82 ng/mL and 0.45 ng/mL, respectively. Based on our proposed theory, the affinity constants of SARS-CoV-2 IgM or IgG antibody and their respective secondary antibodies were also determined. The FRMB can be readily extended as a universal platform for the label-free, rapid, and sensitive in situ/on-site measurement of other biomarkers and the investigation of biomolecular interaction.

Indexed as

Antibodies, ViralBiosensing TechniquesCOVID-19COVID-19 Serological TestingHumansImmunoassayImmunoglobulin GImmunoglobulin MLimit of DetectionMicrofluidic Analytical TechniquesSARS-CoV-2Sensitivity and SpecificitySpike Glycoprotein, CoronavirusAntibodies, ViralImmunoglobulin GImmunoglobulin MSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Fresnel reflection biosensorImmunoglobulin GImmunoglobulin MPoint-of-care testingSARS-CoV-2

Identifiers

PMID34278534
PMCPMC8286882
OpenAlexW3185860018

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.